Insider · CIK 0001608601
Christopher Bowden
Files at BCAX (Bicara Therapeutics Inc.). First filing -, latest -.
Christopher Bowden files SEC Form 4 as director at BCAX (Bicara Therapeutics Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Christopher Bowden has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 9, 2026 | BCAX Bicara Therapeutics Inc. | AGrant or award Stock Option (Right to Buy)derivative | +19,475 | $0.00 | $0 | 19,475 | Jun 10, 2026 |
| Jun 9, 2025 | BCAX Bicara Therapeutics Inc. | AGrant or award Stock Option (Right to Buy)derivative | +23,746 | $0.00 | $0 | 23,746 | Jun 10, 2025 |
Questions about Christopher Bowden
Answered from the filings on this page, as of the latest one.
Is Christopher Bowden buying or selling?
Christopher Bowden has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Christopher Bowden's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Christopher Bowden has 0.
Where does Christopher Bowden file Form 4?
Christopher Bowden has filed Form 4 at BCAX (Bicara Therapeutics Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.